Adularia AG

Precision Cancer Immunotherapy

Adularia is a preclinical biotech spin-off from the University of Zurich developing novel small molecule cancer immunotherapies. The research of the symbiotic interplay between gut microbes and the immune system led to the identification of GPR84 as a novel therapeutic target for immuno-oncology. We have developed several series of proprietary small-molecule modulators of GPR84 and showed that these molecules are able to reprogram myeloid cells in cancer, causing an enhanced anti-tumor immune response. By replicating this natural mechanism with a synthetic small molecule, we aim to deliver a highly effective, targeted, and well-tolerated cancer treatment. We are advancing toward IND-enabling studies by mid-2027 and are currently raising seed funding to complete our preclinical program.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
REGISTER

No Jobs

Videos

Impact Clip: Adularia - Gebert Rüf Stiftung

Documents

NC deck
TOP 100 Swiss Startup Award

The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.

TOP 100 Swiss Startups 2024 TOP 100 Swiss Startups 2023

Website

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (150'000) 2023

Website

Venture Leaders Biotech

Venture Leaders Biotech 2022

Adularia AG

Precision Cancer Immunotherapy

Website:
www.adularia.ch

Headquarter:
Zurich

Foundation Date:
September 2022

Technology:

  • Biotech

Sectors:

  • Biotech
  • Cancer
  • Drug development platforms
  • Drug discovery
  • Machine Learning / AI
  • Research and development
  • Small molecule drugs

Support received

  • Support venture leaders
  • Support venturekick
  • Support TOP 100